Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19220763 | 0.93 | SOAT1 (0.36) | SOAT1MEN1FAAHTP53CYP1A2 | |
| SCHEMBL19220764 | 0.91 | SOAT1 (0.39) | SOAT1MEN1FAAHTP53CYP1A2 | |
| SCHEMBL6340075 | 0.88 | MAPK1 (0.32) | SOAT1MEN1FAAHTP53CYP1A2 | |
| SCHEMBL16350179 | 0.81 | ALDH1A1 (0.41) | MAPK1CYP4F2CYP4A11 | |
| SCHEMBL2311055 | 0.81 | ALDH1A1 (0.46) | MEN1KMT2A | |
| SCHEMBL26263694 | 0.79 | FAAH (0.31) | MEN1FAAHCYP1A2KMT2AMAPK1 | |
| SCHEMBL20929115 | 0.79 | — | — | |
| SCHEMBL16968099 | 0.77 | TDP1 (0.38) | KMT2ACYP4F2CYP4A11 | |
| SCHEMBL16656154 | 0.77 | EPHX2 (0.38) | MEN1KMT2A | |
| SCHEMBL12516792 | 0.76 | PDK2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774079-B2 | Quinazoline derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-09-15 | — | — | US | disclosed |
| US-10421754-B2 | Quinazoline derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2019-09-24 | — | — | US | disclosed |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
| US-9718825-B2 | N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2017-08-01 | — | — | US | disclosed |
| US-9718825-B2 | N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2017-08-01 | — | — | US | disclosed |
| US-20160024097-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2016-01-28 | — | — | US | disclosed |
| US-8193214-B2 | Chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-05 | — | — | US | disclosed |
| US-20100029637-A1 | Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | US | disclosed |
| EP-0815084-B1 | LACTAM-CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEASE | PROCTER & GAMBLE (US) | 2003-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029637-A1 | Chymase Inhibitors | CMA1, CPA3, SERPINB1 | SOAT1 3493/4885MEN1 1367/4885FAAH 1066/4885 |
| US-10774079-B2 | Quinazoline derivative | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | SOAT1 1952/4885MEN1 2146/4885FAAH 4627/4885 |
| US-20160024097-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK1, SGK3, SGK2 | SOAT1 2433/4885MEN1 4228/4885FAAH 4518/4885 |
| US-10421754-B2 | Quinazoline derivative | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | SOAT1 1952/4885MEN1 2146/4885FAAH 4627/4885 |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | SOAT1 1952/4885MEN1 2146/4885FAAH 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.